Published in Annu Rev Immunol on January 01, 2008
Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol (2013) 4.33
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A (2008) 3.55
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci (2013) 1.77
High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics (2011) 1.70
Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. Comp Med (2012) 1.61
Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum (2010) 1.52
Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells. J Exp Med (2010) 1.51
Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs (2013) 1.50
Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc (2012) 1.44
Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol (2011) 1.34
Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol (2009) 1.34
Targeting B cells and antibody in transplantation. Am J Transplant (2011) 1.34
Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol (2009) 1.31
Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol (2009) 1.29
Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol (2009) 1.27
Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol (2014) 1.19
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.18
Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. Biochemistry (2008) 1.17
Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One (2012) 1.16
Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience (2008) 1.16
Advances in the understanding of the mechanism of action of IVIg. J Neurol (2008) 1.15
Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. J Am Chem Soc (2011) 1.14
The challenge and promise of glycomics. Chem Biol (2014) 1.13
Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J Am Chem Soc (2012) 1.12
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol (2012) 1.11
Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol (2009) 1.11
Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun (2015) 1.11
N-linked glycosylation selectively regulates autonomous precursor BCR function. Nat Immunol (2010) 1.11
Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk. J Intern Med (2009) 1.09
Emerging antibody products and Nicotiana manufacturing. Hum Vaccin (2011) 1.08
Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep (2014) 1.06
T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J Clin Invest (2013) 1.06
Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am (2010) 1.06
Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research. Mol Cell Proteomics (2014) 1.06
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood (2013) 1.03
Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol (2014) 1.02
Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol (2010) 1.00
Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology (2015) 0.99
Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.99
The Japanese guidelines for the management of sepsis. J Intensive Care (2014) 0.99
Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1. Circ Res (2012) 0.98
Fetal intraperitoneal injection of immunoglobulin diminishes alloimmune hemolysis. J Perinatol (2011) 0.98
Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog (2011) 0.98
Remarkable transglycosylation activity of glycosynthase mutants of endo-D, an endo-β-N-acetylglucosaminidase from Streptococcus pneumoniae. J Biol Chem (2012) 0.97
Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc (2013) 0.96
The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease. Cardiol Res Pract (2012) 0.95
DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci U S A (2009) 0.94
Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions. Chem Biol (2014) 0.91
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
Influence of Intravenous Immunoglobulin Treatment on Thrombopoiesis. Transfus Med Hemother (2012) 0.91
Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol (2010) 0.90
The other side of immunoglobulin G: suppressor of inflammation. Clin Exp Immunol (2009) 0.89
Human plasma protein N-glycosylation. Glycoconj J (2015) 0.88
Cellular and molecular mechanisms of immunomodulation in the brain through environmental enrichment. Front Cell Neurosci (2014) 0.87
Role of IgA and IgA fc receptors in inflammation. J Clin Immunol (2009) 0.87
Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol (2009) 0.86
The role of IgA and IgA Fc receptors as anti-inflammatory agents. J Clin Immunol (2010) 0.85
Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc Natl Acad Sci U S A (2013) 0.85
Regulation of immune responses by the neonatal fc receptor and its therapeutic implications. Front Immunol (2015) 0.85
Polyvalent immunoglobulins: challenges and perspectives. Blood Transfus (2013) 0.84
Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun (2014) 0.83
Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation (2013) 0.83
Cross-presentation of IgG-containing immune complexes. Cell Mol Life Sci (2012) 0.83
The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade. J Clin Immunol (2012) 0.83
The contribution of allergen-specific IgG to the development of th2-mediated airway inflammation. J Allergy (Cairo) (2012) 0.83
Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects. Front Immunol (2015) 0.83
Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody. Immunotherapy (2012) 0.83
Evolutional and clinical implications of the epigenetic regulation of protein glycosylation. Clin Epigenetics (2011) 0.82
Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol (2014) 0.82
Challenges with sensitized recipients in pediatric heart transplantation. Clinics (Sao Paulo) (2014) 0.81
Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol (2013) 0.81
A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola. Mol Microbiol (2013) 0.81
Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation. MAbs (2015) 0.80
Intravenous immunoglobulin in the management of lupus nephritis. Autoimmune Dis (2012) 0.80
Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clin Exp Immunol (2009) 0.80
Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev (2013) 0.80
Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation (2012) 0.80
Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells? Clin Exp Immunol (2011) 0.79
Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol (2013) 0.79
Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies. F1000Res (2013) 0.78
Tregitopes switch on Tregs. Blood (2008) 0.78
Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78
Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Semin Immunopathol (2014) 0.77
Redox Proteomic Profiling of Specifically Carbonylated Proteins in the Serum of Triple Transgenic Alzheimer's Disease Mice. Int J Mol Sci (2016) 0.77
Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro. PLoS One (2013) 0.77
Advances in the treatment of pulmonary tuberculosis. J Thorac Dis (2012) 0.77
Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity. Front Immunol (2015) 0.76
Mechanisms of Autoantibody-Induced Pathology. Front Immunol (2017) 0.76
Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute. Clin Exp Med (2013) 0.76
Essential role of NK cells in IgG therapy for experimental autoimmune encephalomyelitis. PLoS One (2013) 0.76
A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines. Immun Inflamm Dis (2014) 0.76
Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice. Med Microbiol Immunol (2014) 0.76
Occurrence of autoantibodies for gastrointestinal autoimmune diseases in children with common variable immune deficiency and selected IgA deficiency. Prz Gastroenterol (2013) 0.76
sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion. J Clin Immunol (2010) 0.76
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A (2008) 3.55
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63
Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med (2002) 2.54
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med (2006) 2.44
Fc-receptors as regulators of immunity. Adv Immunol (2007) 2.38
Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J Exp Med (2003) 2.23
Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A (2005) 2.22
Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 2.20
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10
Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med (2006) 2.00
The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol (2004) 1.95
Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A (2006) 1.91
Antibodies, Fc receptors and cancer. Curr Opin Immunol (2007) 1.89
Antibody-mediated modulation of immune responses. Immunol Rev (2010) 1.84
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med (2007) 1.84
Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science (2005) 1.81
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med (2002) 1.77
General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A (2013) 1.69
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A (2007) 1.66
Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A (2012) 1.62
Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood (2005) 1.55
Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J Exp Med (2007) 1.53
FcγRs in health and disease. Curr Top Microbiol Immunol (2011) 1.51
Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med (2007) 1.51
Novel roles for the IgG Fc glycan. Ann N Y Acad Sci (2012) 1.51
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A (2010) 1.46
In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A (2008) 1.44
Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol (2007) 1.34
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol (2007) 1.32
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A (2012) 1.23
Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity (2002) 1.19
Analyzing antibody-Fc-receptor interactions. Methods Mol Biol (2008) 1.19
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest (2016) 1.12
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res (2003) 1.11
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci U S A (2012) 1.11
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med (2010) 1.10
Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol (2008) 1.08
Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res (2002) 1.08
Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun (2012) 1.05
Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol (2008) 1.04
FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J Immunol (2008) 1.03
Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum (2009) 1.00
Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol (2008) 1.00
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood (2003) 0.96
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc Natl Acad Sci U S A (2013) 0.96
Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest (2014) 0.95
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle (2012) 0.94
New nomenclature for Fc receptor-like molecules. Nat Immunol (2006) 0.94
Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res (2004) 0.94
Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. J Exp Med (2005) 0.93
Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am J Pathol (2003) 0.92
Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J Immunol (2011) 0.86
Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms. J Immunol (2014) 0.85
Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc Natl Acad Sci U S A (2013) 0.85
Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol (2013) 0.84
A critical role for Fc gamma RIIB in the induction of rheumatoid factors. J Immunol (2004) 0.82
humanized mice to study FcγR function. Curr Top Microbiol Immunol (2014) 0.81
Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc. Proc Natl Acad Sci U S A (2013) 0.81
Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease. Am J Pathol (2007) 0.81
Killing some to make way for others. Nat Immunol (2007) 0.79
The Role and Function of Fcγ Receptors on Myeloid Cells. Microbiol Spectr (2016) 0.75
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell (2015) 0.75
Closing the circle. Jeffrey V. Ravetch, M.D., Ph.D. Interviewed by Lynne Lederman. Biotechniques (2008) 0.75